OakChart

Immucell Corp

ICCCHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 3:59 PM ET

10.19-0.07 (-0.68%)
2026-11-11 22:55 CET
Market cap
93.18 USD m
Revenue, TTM
30.68 USD m
Net income, TTM
0.79 USD m
Free cash flow, TTM
4.21 USD m
EPS diluted, TTM
0.08
P/E
121.45
Compare

Price

ICCC against its 20, 50 and 200-day averages
2050200earnings
8.0010.0012.0059K118KVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ICCCclose 10.1920-day 10.3450-day 10.08200-day 9.0110.1952w high

15.8% under the 52-week high of 12.10 on 14 Jul 2026. 52-week low 4.52 on 21 Nov 2025. Last 15 sessions, 10.9% high to low

Volume 0.20× normal · the line is the 50-bar volume average

Profile

ICCC
52-week range, 75% of the way up
4.5212.10

ImmuCell Corp. engages in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. It operates through the following segments: Scours and Mastitis. The Scours segment consists of the First Defense product line. The Mastitis segment includes the CMT product line consisting of reagents and equipment used for rapid cow-side testing to identify mastitic quarters by detecting elevated somatic cell counts. The company was founded in 1982 and is headquartered in Portland, ME.

Employees73
IPOMay 05, 1987
Beta0.62
ATR, 14d0.34
Rel volume0.20
Short float0.26%
Insider own37.62%
Inst own15.17%

Snapshot

6 groups

Valuation

Index-
Market Cap92.54M
Enterprise Value96.13M
Income0.79M
Sales30.68M
Book/sh3.45
Cash/sh0.98
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees73
IPOMay 05, 1987

Ratios

P/E121.45
Forward P/E-
PEG-
P/S3.02
P/B2.95
P/C10.45
P/FCF21.98
EV/EBITDA22.62
EV/Sales3.13
Quick Ratio2.71
Current Ratio4.75
Debt/Eq0.40
LT Debt/Eq0.34
Option/ShortNo / Yes

Earnings

EPS (ttm)0.08
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y29.01% 4.06%
Sales past 3/5Y14.19% 12.50%
EPS Y/Y TTM-54.03%
Sales Y/Y TTM8.49%
EPS Q/Q258.99%
Sales Q/Q11.50%
EarningsNov 12 AMC
EPS/Sales Surpr.- -

Ownership

Insider Own37.62%
Insider Trans0.23%
Inst Own15.17%
Inst Trans-0.96%
ROA1.69%
ROE2.57%
ROIC1.87%
Gross Margin40.32%
Oper. Margin6.08%
Profit Margin2.57%
SMA20-1.44%
SMA501.07%
SMA20013.08%
Trades-

Technical

Shs Outstand9.08M
Shs Float5.67M
Short Float0.26%
Short Ratio0.89
Short Interest0.01M
52W High12.10 -15.79%
52W Low4.52 125.44%
Volatility4.32% 2.91%
ATR (14)0.34
RSI (14)49.47
Beta0.62
Rel Volume0.20
Avg Volume16.51K
Volume3,371

Performance

Perf Week-1.74%
Perf Month-5.56%
Perf Quarter-6.51%
Perf Half Y21.89%
Perf YTD65.69%
Perf Year62.52%
Perf 3Y88.70%
Perf 5Y10.64%
Perf 10Y97.48%
Recom-
Target Price-
Prev Close10.26
Price10.19
Change %-0.68%

Peers

Mkt cap
TickerCompanyMkt cap
PAHCPhibro Animal Health Corp1.43B
ELANElanco Animal Health Inc13.24B
ZTSZoetis Inc33.55B
JAGXJaguar Health Inc6.44M
NEOGNeogen Corp2.53B
XBITXBiotech Inc59.45M
MCRBSeres Therapeutics Inc15.29M
IDXXIdexx Laboratories Inc55.35B
PETSPetmed Express Inc23.09M
CENTCentral Garden & Pet Co2.62B

Insider trading

6 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
te Boekhorst Paul Francis OlivPresident and CEOJun 18 '26Buy9.498,00075,96017,785Jun 22 08:33 AM
BRIGHAM MICHAEL FDirectorMar 20 '26Option Exercise5.8425,000146,000229,752Mar 24 07:57 PM
te Boekhorst Paul Francis OlivPresident and CEODec 03 '25Buy5.026,07730,5369,785Dec 03 04:14 PM
te Boekhorst Paul Francis OlivPresident and CEODec 02 '25Buy4.873,70818,0533,708Dec 03 04:14 PM
Tomsche David ScottDirectorNov 25 '25Buy4.761,6337,7814,740Nov 28 08:12 AM
Tomsche David ScottDirectorNov 25 '25Buy4.761,6337,77352,720Nov 28 08:12 AM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B
DFACU.S. Core Equity 2 Portfolio-ETF Class SharesAUM: 49.14B
DFATU.S. Targeted Value Portfolio-ETF Class SharesAUM: 14.47B
DXUVUS Vector Equity Portfolio ETF Class SharesAUM: 665.71M
DCORUS Core Equity 1 Portfolio ETF Class SharesAUM: 3.65B
DFMCU.S. Micro Cap Portfolio ETF Class SharesAUM: 212.10M
DFSUDimensional US Sustainability Core 1 ETFAUM: 2.38B

News

latest 14 of 198
  • ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2026 (GlobeNewswire)
  • ImmuCell Announces a 46% Increase in Product Sales in Quarter Three of 2026, Based on Preliminary, Unaudited Sales Results (GlobeNewswire) +12.40%
  • Top Research Reports for Alphabet, Mastercard & AbbVie (Zacks)
  • ImmuCell Corp (ICCC) (Q2 2026) Earnings Call Highlights: Record Net Income and Market Share ... (GuruFocus.com) -7.80%
  • ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2026 (GlobeNewswire)
  • ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2026 (GlobeNewswire)
  • ImmuCell Announces a 12% Increase in Product Sales in Q2 of 2026 and a 21% Increase in the First Six Months of 2026, Based on Preliminary, Unaudited Sales Results (GlobeNewswire) +7.76%
  • ImmuCell Corp (ICCC) Q1 2026 Earnings Call Highlights: Record Revenue and Strategic Growth (GuruFocus.com) +7.99% +11.10%
  • ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2026 (GlobeNewswire)
  • ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2026 (GlobeNewswire)
  • ImmuCell Bolsters its Innovation Strategy with Appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to the Board, and Moves to a Smaller Board of Independent Directors (GlobeNewswire) +8.72%
  • ImmuCell Announces a 28.4% Increase in Product Sales in Q1 of 2026, based on Preliminary, Unaudited Sales Results (GlobeNewswire) +12.70%
  • ImmuCell Appoints Former Elanco Animal Health Board Member Kathy Turner to Board (GlobeNewswire)
  • ImmuCell Corp (ICCC) Q4 2025 Earnings Call Highlights: Navigating Growth Amidst Challenges (GuruFocus.com)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q12026-05-14--0.21510.36--
2025Q42026-03-04---0.3157.63--
2025Q32025-11-13---0.0155.51--
2025Q22025-08-14--0.0566.45--
2025Q12025-05-14--0.1618.07--
2023Q42025-02-25---0.1475.10--
2024Q42025-01-10--0.0587.80--
2024Q32024-11-13---0.0866.01--
2024Q22024-08-13---0.1965.47--
2024Q12024-05-14---0.0577.26--
2023Q32023-11-13---0.1215.40--
2023Q22023-08-10---0.1783.53--
2023Q12023-05-11---0.2993.45--
2022Q42023-01-09---0.2153.91--
2022Q32022-11-21---0.0854.80--
2022Q22022-08-11---0.0883.86--

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-0.140--0.14215.34-
2021FY-0.010--19.24-

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
No estimate revisions.

Estimate history

EPS, annual-0.03-0.423-0.19-0.142-0.01-0.322-0.745-0.264-0.1150.0839
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.196-0.0860.0580.1610.056-0.015-0.3150.2150.2
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual10.43110.98613.72315.34219.24318.56817.47226.49327.64430.68
Period201720182019202020212022202320242025TTM
Sales, quarterly5.4736.0127.7518.0676.4455.5067.62610.3577.186
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual5.4765.5697.2137.2197.7427.7477.7518.9799.0469.082
Period201720182019202020212022202320242025MRQ
Shares, quarterly7.8338.8338.9798.9839.0469.0469.0469.0479.082
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue30.6827.6426.4917.4718.5719.2415.3413.7210.99
Cost of Goods Sold Incl. D&A18.3116.2018.5513.6012.6310.598.488.925.79
Gross Profit12.3711.457.943.875.948.666.864.805.19
Selling, General and Administrative Excl. Other10.509.809.589.628.248.408.245.767.34
Research and Development1.893.043.904.393.094.174.352.073.52
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income1.871.65-1.64-5.75-2.300.26-1.38-0.95-2.15
Interest Expense0.440.490.570.480.350.310.320.430.43
Unusual Expense0.672.240.000.000.000.00-0.84--
Net Income Before Taxes0.85-1.03-2.15-5.77-2.49-0.07-1.03-1.27-1.86
Income Taxes0.070.010.010.000.010.01-0.010.030.46
Consolidated Net Income0.79-1.04-2.16-5.77-2.49-0.08-1.02-1.30-2.32
Net Income From Continuing Operations0.79-1.04-2.16-5.77-2.49-0.08-1.02-1.30-2.32
Net Income0.79-1.04-2.16-5.77-2.49-0.08-1.02-1.30-2.32
EPS (Recurring)0.140.06-0.26-0.75-0.32-0.01-0.22-0.19-0.42
EPS (Basic, Before Extraordinaries)0.09-0.12-0.26-0.75-0.32-0.01-0.14-0.19-0.42
EPS (Diluted)0.08-0.12-0.26-0.75-0.32-0.01-0.14-0.19-0.42
EBITDA4.254.381.05-3.030.192.730.981.31-0.63
Non-Operating Income (Expense)0.090.060.060.450.16-0.01-0.180.120.71
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.440.230.260.290.210.140.180.230.27
Price To Earnings Ratio122.29122.29-------
Price To Sales Ratio3.012.011.592.262.543.162.802.563.52
Gross Margin40.3241.4029.9722.1532.0144.9844.7334.9947.28
Operating Margin6.085.97-6.19-32.90-12.381.34-9.00-6.95-19.54
Net Margin2.57-3.76-8.14-33.05-13.43-0.41-6.66-9.44-21.13
Shares Outstanding9.089.058.987.757.757.747.227.215.57
Market Capitalization93.1893.1845.8939.4547.2661.9442.9237.1338.65

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue7.1910.367.635.516.448.077.756.01
Cost of Goods Sold Incl. D&A4.755.704.723.143.634.714.924.43
Gross Profit2.444.662.912.362.823.352.831.58
Selling, General and Administrative Excl. Other2.502.692.972.342.252.242.212.16
Research and Development0.120.320.760.690.830.760.820.79
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-0.071.97-0.060.020.571.120.62-0.57
Interest Expense0.100.100.110.130.120.130.140.14
Unusual Expense-2.000.002.670.000.000.000.000.00
Net Income Before Taxes1.881.95-2.85-0.140.501.450.52-0.70
Income Taxes0.050.010.000.000.000.000.010.00
Consolidated Net Income1.831.94-2.85-0.140.501.450.52-0.70
Net Income From Continuing Operations1.831.94-2.85-0.140.501.450.52-0.70
Net Income1.831.94-2.85-0.140.501.450.52-0.70
EPS (Recurring)0.050.21-0.11-0.020.060.160.06-0.09
EPS (Basic, Before Extraordinaries)0.200.21-0.32-0.020.060.160.06-0.09
EPS (Diluted)0.200.21-0.32-0.020.060.160.06-0.09
EBITDA0.412.500.650.701.241.791.310.10
Non-Operating Income (Expense)0.040.08-0.01-0.020.060.460.040.02
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.190.110.080.060.050.040.050.06
Price To Earnings Ratio122.29-23.7533.17----
Price To Sales Ratio3.011.912.012.042.221.581.741.24
Gross Margin33.9244.9738.1642.9243.7241.5836.5426.34
Operating Margin-0.9119.01-0.760.368.8413.858.02-9.56
Net Margin25.5318.75-37.36-2.547.7917.946.64-11.67
Shares Outstanding9.089.059.059.059.058.988.988.83
Market Capitalization93.1857.2655.6356.5462.9042.6945.8928.43

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments3.813.760.985.7910.197.958.772.523.80
Short Term Receivables3.453.812.231.802.721.861.681.431.49
Inventories9.277.117.816.043.092.092.522.332.05
Other Current Assets0.420.360.450.360.270.250.220.140.17
Total Current Assets16.9415.0411.4713.9916.2612.1613.196.427.51
Net Property, Plant & Equipment25.4529.9132.1530.6428.0027.9825.2726.0326.07
Total Investments and Advances0.000.000.000.000.000.000.000.040.00
Intangible Assets0.100.110.130.150.170.190.210.230.25
Deferred Tax Assets-------0.000.47
Other Assets0.040.030.060.080.030.030.030.010.00
Total Assets42.5345.1043.8144.8644.4740.3538.6932.7334.30
Short Term Debt Incl. Current Port. of LT Debt1.701.932.071.070.920.861.271.340.32
Accounts Payable0.800.940.890.790.750.600.570.601.22
Income Tax Payable0.010.010.000.000.00----
Other Current Liabilities1.481.531.231.210.870.750.650.620.53
Total Current Liabilities3.984.414.203.072.532.212.502.572.06
Long Term Debt11.5013.1714.6211.419.359.877.158.428.64
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.000.060.000.00
Total Liabilities15.4817.5818.8214.4811.8912.089.7010.9910.70
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity27.0627.5224.9930.3832.5828.2728.9921.7423.59
Total Shareholders Equity27.0627.5224.9930.3832.5828.2728.9921.7423.59
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity27.0627.5224.9930.3832.5828.2728.9921.7423.59
Total Liabilities & Stockholders Equity42.5345.1043.8144.8644.4740.3538.6932.7334.30
Book Value Per Share2.993.063.223.924.213.924.023.904.31
Tangible Book Value Per Share2.983.053.213.904.193.893.993.864.26
Full-Time Employees737579746761545147
Price to Book Ratio2.971.721.531.481.901.521.281.802.12
Return on Assets-2.37-4.85-13.03-5.58-0.18-2.59-3.63-6.93-0.57
Return on Equity-3.81-8.21-20.86-7.92-0.26-3.57-5.11-10.24-0.78
Return on Invested Capital-2.70-5.30-14.58-5.97-0.19-2.68-3.59-7.70-0.52
Quick Ratio1.931.800.872.595.204.554.281.592.64
Current Ratio4.263.412.734.566.425.505.292.503.64

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income0.79-1.04-2.16-5.77-2.49-0.08-1.02-1.30-2.32
Depreciation2.382.732.692.722.522.472.362.271.52
Other Funds (Non Cash)3.202.840.230.500.270.18-0.540.33-0.34
Funds from Operations6.374.530.76-2.560.292.580.781.33-0.68
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-0.48-2.05-0.41-2.11-1.83-1.620.53-1.100.30
Cash from Operating Activities5.892.480.36-4.67-1.540.951.320.23-0.37
Capital Expenditures-1.68-1.25-0.47-1.89-3.98-2.61-4.07-1.39-2.03
Net Assets From Acquisitions0.000.000.000.000.000.000.00-0.01-0.01
Sale of Fixed Assets and Businesses0.020.040.000.000.010.020.050.450.25
Purchase or Sale of Investments0.000.000.000.000.001.001.46-2.450.00
Purchase of Investments0.000.000.000.000.000.00-1.99-10.120.00
Sale Or Maturity of Investments0.000.000.000.000.001.003.457.670.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-1.66-1.21-0.46-1.89-3.96-1.60-2.57-3.40-1.79
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock0.160.284.360.020.034.249E-068.300.10
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock0.160.284.360.020.034.249E-068.300.10
Proceedsfrom Stock Options0.000.284.360.000.004.230.008.300.00
Issuance or Reduction of Debt, Net-1.53-1.49-1.471.731.08-0.371.91-1.360.79
Change in Long Term Debt-1.53-1.49-1.471.731.08-0.371.91-0.860.29
Issuance of Long Term Debt0.790.790.002.921.980.4011.480.000.69
Reduction of Long Term Debt-2.32-2.28-1.47-1.19-0.90-0.77-9.57-0.86-0.40
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities-1.37-1.212.881.751.113.881.916.940.89
Net Change in Cash2.860.052.78-4.81-4.393.240.663.77-1.28
Free Cash Flow4.211.22-0.11-6.57-5.52-1.65-2.76-1.16-2.40
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow21.9145.32-------
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.00-0.010.020.46

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments8.866.813.813.896.004.60
Short Term Receivables2.902.733.452.612.423.40
Inventories9.088.679.279.808.297.36
Other Current Assets0.240.650.420.530.420.56
Total Current Assets21.0818.8616.9416.8317.1415.92
Net Property, Plant & Equipment25.4225.1225.4528.7629.4329.55
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.100.100.100.100.110.11
Other Assets0.030.030.040.040.050.05
Total Assets46.6344.1142.5345.7346.7245.62
Short Term Debt Incl. Current Port. of LT Debt1.631.721.701.671.861.90
Accounts Payable0.951.000.800.971.300.99
Income Tax Payable0.050.010.010.000.000.00
Other Current Liabilities1.801.191.481.351.280.98
Total Current Liabilities4.443.913.984.004.453.87
Long Term Debt10.8211.0611.5011.9312.4112.76
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities15.2614.9715.4815.9316.8516.63
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity31.3729.1427.0629.8029.8728.99
Total Shareholders Equity31.3729.1427.0629.8029.8728.99
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity31.3729.1427.0629.8029.8728.99
Total Liabilities & Stockholders Equity46.6344.1142.5345.7346.7245.62
Book Value Per Share3.453.222.993.293.303.23
Tangible Book Value Per Share3.443.212.983.283.293.22
Full-Time Employees--73---
Price to Book Ratio2.972.121.871.892.161.56
Return on Assets1.69-1.22-2.375.153.98-0.61
Return on Equity2.57-1.88-3.818.276.61-1.01
Return on Invested Capital4.354.83-7.39-0.331.193.47
Quick Ratio2.712.601.931.761.992.21
Current Ratio4.754.824.264.213.854.12

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income1.831.94-2.85-0.140.501.45
Depreciation0.470.530.710.680.670.68
Other Funds (Non Cash)0.260.162.84-0.060.030.03
Funds from Operations2.572.630.700.481.202.15
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.450.95-0.22-1.660.40-0.58
Cash from Operating Activities3.023.570.48-1.181.601.57
Capital Expenditures-0.73-0.18-0.17-0.59-0.16-0.33
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.010.010.000.030.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.73-0.17-0.17-0.59-0.13-0.33
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.164E-060.000.000.30-0.02
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.164E-060.000.000.30-0.02
Proceedsfrom Stock Options0.000.000.000.000.30-0.02
Issuance or Reduction of Debt, Net-0.40-0.40-0.39-0.34-0.38-0.38
Change in Long Term Debt-0.40-0.40-0.39-0.34-0.38-0.38
Issuance of Long Term Debt0.000.000.000.790.000.00
Reduction of Long Term Debt-0.40-0.40-0.39-1.12-0.38-0.38
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities-0.24-0.40-0.39-0.34-0.08-0.40
Net Change in Cash2.053.01-0.08-2.111.400.84
Free Cash Flow2.293.400.31-1.781.451.24
Price to Free Cash Flow21.9116.9645.4279.0335.6354.53

Revenue breakdown

Americas2024: 22.89M 2025: 24.39M
Non-US2024: 3.60M 2025: 3.25M
Corporate Segment, Mastitis2024: 178.92K 2025: 196.39K
Corporate Segment, Scours2024: 26.31M 2025: 27.45M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.26%0.0M5.7M17.97K
2026-10-150.32%0.0M5.7M20.49K
2026-09-300.39%0.0M5.7M25.04K
2026-09-150.35%0.0M5.7M28.58K
2026-08-310.34%0.0M5.7M29.19K
2026-08-140.27%0.0M5.7M31.00K
2026-07-310.31%0.0M5.6M30.10K
2026-07-150.25%0.0M5.6M30.42K
2026-06-300.33%0.0M5.6M28.96K
2026-06-150.22%0.0M5.6M25.56K
2026-05-290.16%0.0M5.6M25.07K
2026-05-150.19%0.0M5.6M20.01K
2026-04-300.32%0.0M5.7M18.30K
2026-04-150.48%0.0M5.7M18.66K
2026-03-310.61%0.0M5.6M17.71K
2026-03-130.48%0.0M5.6M23.22K
2026-02-270.28%0.0M5.6M24.04K
2026-02-130.32%0.0M5.6M26.49K
2026-01-300.22%0.0M5.6M25.63K
2026-01-150.19%0.0M5.6M25.05K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-138-KCurrent report2026-10-12SEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-138-KCurrent report2026-08-13SEC
2026-07-098-KCurrent report2026-07-09SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-18SEC
2026-06-178-KCurrent report2026-06-11SEC
2026-06-108-KCurrent report2026-06-04SEC
2026-05-148-KCurrent report2026-05-14SEC
2026-05-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-1310-K/A2025-12-31SEC
2026-05-088-KCurrent report2026-05-08SEC
2026-04-24DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-11SEC
2026-04-233Initial statement of beneficial ownership of securities2026-04-15SEC
2026-04-233Initial statement of beneficial ownership of securities2026-04-15SEC
2026-04-164Statement of changes in beneficial ownership of securities2026-04-15SEC
2026-04-164Statement of changes in beneficial ownership of securities2026-04-15SEC
2026-04-164Statement of changes in beneficial ownership of securities2026-04-15SEC
2026-04-164Statement of changes in beneficial ownership of securities2026-04-15SEC
2026-04-14PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-11SEC
2026-04-144Statement of changes in beneficial ownership of securities2025-04-16SEC
2026-04-144Statement of changes in beneficial ownership of securities2025-04-16SEC
2026-04-144Statement of changes in beneficial ownership of securities2025-04-16SEC
2026-04-144Statement of changes in beneficial ownership of securities2025-04-16SEC
2026-04-144Statement of changes in beneficial ownership of securities2025-04-16SEC
2026-04-144Statement of changes in beneficial ownership of securities2025-04-16SEC
2026-04-148-KCurrent report2026-04-07SEC
2026-04-088-KCurrent report2026-04-08SEC
2026-04-013Initial statement of beneficial ownership of securities2026-04-01SEC
2026-03-3010-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-244Statement of changes in beneficial ownership of securities2026-03-20SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-0675.96K100
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-1248.59K200
2025-1115.55K200

Institutional holders

Manager% owned
VANGUARD CAPITAL MANAGEMENT LLC2.96%
MORGAN STANLEY2.59%
RENAISSANCE TECHNOLOGIES LLC1.89%
Cresset Asset Management, LLC1.50%
GEODE CAPITAL MANAGEMENT, LLC0.80%
DIMENSIONAL FUND ADVISORS LP0.67%
Bleichroeder LP0.55%
Steadtrust LLC0.50%
Mesirow Financial Investment Management, Inc.0.47%
CITADEL ADVISORS LLC0.45%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.00%
VANGUARD EXTENDED MARKET INDEX FUND0.87%
Fidelity Extended Market Index Fund0.37%
iShares Micro-Cap ETF0.23%
U.S. CORE EQUITY 2 PORTFOLIO0.20%
Fidelity Total Market Index Fund0.15%
Nationwide Bailard Small Cap Value Fund0.11%
Fidelity Series Total Market Index Fund0.10%
VANGUARD INSTITUTIONAL TOTAL STOCK MARKET INDEX FUND0.06%
U.S. Targeted Value Portfolio0.05%

OakChart. ICCC. Cached 15 minutes.

Some panels did not load: ratings.